RO7790121 Placebo
Sponsors
F. Hoffmann-La Roche AG
Conditions
Moderate to Severe Atopic Dermatitis (AD)Moderate to Severe Rheumatoid Arthritis (RA)Moderately to Severely Active Crohn's Disease (CD)Moderately to Severely Active Ulcerative Colitis (UC)
Phase 2
A Phase II, Multicenter, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Atopic Dermatitis
RecruitingCTIS2024-515494-95-00
Start: 2025-05-26Target: 71Updated: 2026-01-27
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors
RecruitingCTIS2025-521034-28-00
Start: 2025-12-05Target: 63Updated: 2026-01-26
Phase 3
A PHASE III, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREAT-THROUGH STUDY TO ASSESS THE EFFICACY AND SAFETY OF INDUCTION AND MAINTENANCE THERAPY WITH RO7790121 IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
Active, not recruitingCTIS2024-513014-35-00
Start: 2024-11-13Target: 348Updated: 2025-12-15
A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy with RO7790121 in Patients with Moderately to Severely Active Ulcerative Colitis
RecruitingCTIS2024-513015-27-00
Start: 2025-01-09Target: 217Updated: 2025-12-19
A Phase III, Multicenter, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Induction Therapy with RO7790121 in Patients with Moderately to Severely Active Crohn's Disease
RecruitingCTIS2024-513054-30-00
Start: 2025-04-16Target: 225Updated: 2026-01-20
A Phase III, Multicenter, Double-Blind, Placebo Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy with RO7790121 in Patients with Moderately to Severely Active Crohn's Disease
RecruitingCTIS2024-513053-69-00
Start: 2025-04-16Target: 348Updated: 2026-01-12